

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

12th August, 2025

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)

Dear Sir(s)/Madam,

Pursuant to Regulation to 30 of the SEBI LODR Regulations, we wish to inform you that Alkem Laboratories Limited (“**Company**”) has, pursuant to a shareholders’ agreement dated 12th August, 2025, agreed to incorporate a subsidiary company (“**Subsidiary**”) in the Kingdom of Saudi Arabia. Pursuant to incorporation of such subsidiary, the Company will hold 51% of the total share capital. The balance stake of 49% will be held by Mr. Abdulaziz Alsheikh (“**Saudi Partner**”).

The details as required under SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are enclosed herewith as Annexure I.

The above information is also available on the website of the Company at www.alkemlabs.com.

Kindly take the same on records.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

1) name of the target entity, details in brief such as size, turnover etc.	The Subsidiary is yet to be incorporated.
2) whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition does not fall under related party transaction. None of the promoter / promoter group / group companies have any interest in the entity.
3) industry to which the entity being acquired belongs	Pharmaceuticals and Nutraceuticals
4) objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed investment in the Subsidiary is a strategic investment undertaken by the Company with the objective of expanding the Company’s business and market reach to the Kingdom of Saudi Arabia.
5) brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6) indicative time period for completion of the acquisition	The Subsidiary is proposed to be established within a period of one (1) year from the date of execution of the Shareholders’ Agreement.
7) consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration as determined at the time of incorporation of the Subsidiary.
8) cost of acquisition and/or the price at which the shares are acquired	To be determined at the time of incorporation of the Subsidiary.
9) percentage of shareholding / control acquired and / or number of shares acquired:	51% of the total share capital of the Subsidiary.



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

10) brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The Subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia.
--	--